A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors

FC084CSA accelerated doses at 100mg QD, and then started the conventional "3+3" design from 200mg QD.

Inclusion criteria

• Aged 18 to 75 years old male and female.
• Patients with advanced malignant solid tumors who have failed standard treatments.
• According to RECIST 1.1, there is at least one measurable lesion.
• ECOG performance status 0-1.
• Laboratory examination should meet: ① Blood routine: hemoglobin (HGB) ≥85 g/L, neutrophil count (ANC) ≥1.5×10^9/L, platelet count ( PLT) ≥75×10^9/L; ②Blood biochemistry: total bilirubin (TBIL) ≤1.5×upper limit of normal (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3.0×ULN, serum creatinine ( Cr)≤1.5×ULN or calculate the creatinine clearance ≥50 mL/min according to the Cockcroft-Gault formula method.

Exclusion criteria

• Not recovered from the adverse reactions caused by previous anti-tumor treatments (≥CTCAE grade 1).
• Received anti-tumor therapy within 4 weeks before enrollment.
• Participated in other clinical trials within 4 weeks before enrollment and used clinical investigational drugs during this period.
• Have undergone surgery within 4 weeks before enrollment, and the investigator believes that the patient's state has not recovered to the point where the study can be started.
• Patients with ascites (ascites), pleural effusion (pleural effusion) or pericardial effusion that cannot be controlled by drainage or other methods.
• Central nervous system metastases with clinical symptoms.
• With any situations that the researcher considers inappropriate to participate in this research.